Publications by authors named "Chloe Kalish"
Furoscix, a subcutaneous pH-neutral formulation of furosemide, obtained US Food and Drug Administration approval in October 2022 for adult patients with New York Heart Association class II and class III chronic heart failure. This approval marks an anticipated potential shift in the traditional management of decongestive therapy in chronic heart failure patients from the confines of the hospital to more accessible outpatient or home-based care. In this review, we will summarize existing evidence regarding the use of subcutaneous furosemide in comparison to both oral and intravenous formulations, highlighting the demonstrable benefits of its application in both outpatient and inpatient settings, and also discuss several factors that may limit its use.
View Article and Find Full Text PDFObjectives: The aim of this study was to clarify the dynamics of the mitral annulus throughout the cardiac cycle and its relevance to transcatheter mitral valve replacement (TMVR) sizing and case selection.
Background: Limited data are available regarding the relevance of mitral annular (MA) and neo-left ventricular outflow tract (LVOT) dynamics in the overall population presenting with significant mitral valve disease.
Methods: Patients attending a combined surgical-transcatheter heart valve clinic for severe symptomatic mitral valve disease were assessed using multiphase computed tomography.
Article Synopsis
- * In a study of 575 patients not on hemodialysis, it was found that lower GFR was associated with higher peri-procedural stroke rates, particularly in patients with GFR levels below 60 ml/min, while device success rates remained consistent across GFR groups.
- * Despite procedural improvements like low-contrast techniques, patients with renal insufficiency still face poor long-term outcomes, highlighting the need for ongoing research and optimized strategies for managing this population.